ReCode Therapeutics closed an $80 million Series B round of financing that included Pfizer and Sanofi as investors. The startup’s technology uses lipid nanoparticles to deliver genetic medicines, and its two lead programs are for rare lung disorders.
The Menlo Park-based company is building a service for quick at-home health services, such as lab draws and Covid-19 testing. The company is looking to build the “DoorDash for lab draws,” raising $33 million from backers.
Investors had long expected Intersect ENT to be an acquisition target before Medtronic announced its plans to buy the company last week. Better reimbursement for Intersect ENT’s products and elective procedures returning over the summer months might have helped the deal cross the finish line.
DNA sequencing company Pacific Biosciences has reached a $600 million agreement to acquire Omniome, a startup with complementary sequencing technology. The cash and stock deal comes about 18 months after antitrust concerns led PacBio and sequencing giant Illumina to terminate their tie-up.